Folates and S-adenosylmethionine for major depressive disorder

Canadian Journal of Psychiatry

Volumn 57, Issue 7, 2012, Pages 406-413

  Papakostas, George I ^a   Cassiello, Clair F ^a   Iovieno, Nadia ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressant therapy; Augmentation therapy; Folate; L methylfolate; Major depressive disorder; S adenosylmethionine

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FOLIC ACID; FOLIC ACID DERIVATIVE; HOMOCYSTEINE; IMIPRAMINE; LEVO METHYLFOLATE; LITHIUM; METHYLTETRAHYDROFOLATE REDUCTASE; OXIDOREDUCTASE; PLACEBO; S ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; ANOREXIA; BIPOLAR DEPRESSION; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONOTHERAPY; NAUSEA; NONHUMAN; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SIDE EFFECT; SWEATING; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 84871842069     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700703     Document Type: Review

References (91)

1. Bottiglieri T. S-adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002;76(5):1151S-1157S.
2. Baldessarini RJ. The neuropharmacology of S-adenosyl-Lmethionine. Am J Med. 1987;83:95-103.
3. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep. 2003;5(6):460-466.
4. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158S-1161S.
5. Bottiglieri T, Laundry M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69:228-232.
6. Bottiglieri T, Hyland K, Laundry M, et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med. 1992;22:871-876.
7. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Acta Psychiatr Scand. 1989;80(1):78-82.
8. Carney MW, Sheffield BF. Serum folic acid and B12 in 272 psychiatric in-patients. Psychol Med. 1978;8(1):139-144.
9. Wesson VA, Levitt AJ, Joffe RT. Change in folate status with antidepressant treatment. Psychiatry Res. 1994;53:313-322.
10. Lee S, Wing YK, Fong S. A controlled study of folate levels in Chinese inpatients with major depression in Hong Kong. J Affect Disord. 1998;49:73-77.
11. Ghadirian AM, Anath J, Engelsman F. Folic acid deficiency in depression. Psychosomatics. 1980;21:926-929.
12. Tiemeier H, van Tuijl HR, Hofman A, et al. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry. 2002;159(12):2099-2101.
13. Morris MS, Fava M, Jacques PF, et al. Depression and folate status in the US population. Psychother Psychosom. 2003;72:80-87.
14. Wilkinson AM, Anderson DN, Abou-Saleh MT, et al. 5-Methyltetrahydrofolate level in the serum of depressed subjects and its relationship to the outcome of ECT. J Affect Disord. 1994;32:163-168.
15. Fava M, Borus JS, Alpert JE, et al. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997;154(3):426-428.
16. Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004;65(8):1090-1095.
17. Papakostas GI, Iosifescu DV, Renshaw PF, et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005;140(3):301-307.
18. Papakostas GI, Petersen T, Lebowitz BD, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005;8(4):523-528.
19. Alpert M, Silva RR, Pouget ER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol. 2003;23(3):309-313.
20. Levitt AJ, Wesson VA, Joffe RT. Impact of suppression of thyroxine on folate status during acute antidepressant therapy. Psychiatry Res. 1998;79:123-129.
21. Reynolds EH, Preece JM, Bailey J, et al. Folate deficiency in depressive illness. Br J Psychiatry. 1970;117:287-292.
22. Hector M, Burton JR. What are the psychiatric manifestations of vitamin B12 deficiency? J Am Geriatr Soc. 1988;36(12):1105-1112.
23. Bell IR, Edman JS, Morrow FD, et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc. 1991;39(3):252-257.
24. Alarcon RD, Tolbert LC, Monti JA, et al. One-carbon metabolism disturbances in affective disorders. A preliminary report. J Affect Disord. 1985;9(3):297-301.
25. Smythies JR, Alarcon RD, Morere D, et al. Abnormalities of onecarbon metabolism in psychiatric disorders: study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes. Biol Psychiatry. 1986;21(14):1391-1398.
26. Bjelland I, Tell GS, Vollset SE, et al. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry. 2003;60(6):618-626.
27. Arinami T, Yamada N, Yamakawa-Kobayashi K, et al. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet. 1997;74(5):526-528.
28. Hickie I, Scott E, Naismith S, et al. Late-onset depression: genetic, vascular and clinical contributions. Psychol Med. 2001;31(8):1403-1412.
29. Kelly CB, McDonnell AP, Johnston TG, et al. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004;18(4):567-571.
30. Kim JM, Stewart R, Kim SW, et al. Modification by two genes of associations between general somatic health and incident depressive syndrome in older people. Psychosom Med. 2009;71(3):286-291.
31. Lewis SJ, Lawlor DA, Davey Smith G, et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry. 2006;11(4):352-360.
32. Slopien R, Jasniewicz K, Meczekalski B, et al. Polymorphic variants of genes encoding MTHFR, MTR, and MTHFD1 and the risk of depression in postmenopausal women in Poland. Maturitas. 2008;61(3):252-255.
33. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165(1):1-13.
34. Almeida OP, McCaul K, Hankey GJ, et al. Homocysteine and depression in later life. Arch Gen Psychiatry. 2008;65(11):1286-1294.
35. López-León S, Janssens AC, González-Zuloeta Ladd AM, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry. 2008;13(8):772-785.
36. Lanctôt KL, Rapoport MJ, Chan F, et al. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj. 2010;24(7-8):959-969.
37. Naismith S, Hickie I, Ward PB, et al. Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry. 2002;159(12):2096-2098.
38. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders: clinical potential. Drugs. 1993;45(5):623-636.
39. Passeri M, Cucinotta D, Abate G, et al. Oral 5′- methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano). 1993;5(1):63-71.
40. Guaraldi GP, Fava M, Mazzi F, et al. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry. 1993;5(2):101-105.
41. Di Palma C, Urani R, Agricola R, et al. Is methylfolate effective in relieving major depression in chronic alcoholics? A hypothesis of treatment. Curr Ther Res. 1994;55(5):559-567.
42. Godfrey PSA, Toone BK, Carney MWP, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392-395.
43. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121-130.
44. Resler G, Lavie R, Campos J, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15(3):145-152.
45. Coppen A, Chaudhry SSC. Folic acid enhances lithium prophylaxis. J Affect Disord. 1986;10(1):9-13.
46. Alpert JE, Mischoulon D, Rubenstein GE, et al. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002;14(1):33-38.
47. Papakostas GI, Shelton R, Zajecka J, et al. L-methylfolate augmentation of selective serotonin reuptake inhibitors for major depressive disorder: results of two randomized, double-blind trials. Poster presented at the 15th World Congress of Psychiatry, Buenos Aires, Argentina, 2011.
48. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
49. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19(5):427-434.
50. Frankenburg FR. Folate supplementation: is it safe and effective? [letter]. J Clin Psychiatry. 2009;70(5):767; author reply 767-769.
51. Melikian V, Paton A. Site of reduction and methylation of folic acid in man. Lancet. 1971;298:955-957.
52. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2007;16:1325-1329.
53. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297(21):2351-2359.
54. Kim DH, Smith-Warner SA, Spiegelman D, et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010;21:1919-1930.
55. Stevens VL, McCullough ML, Sun J, et al. High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. Gastroenterology. 2011;141(1):98-105.
56. Stahl SM. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry. 2008;69(9):1352-1353.
57. Mischoulon D, Fava M. Are nutritional supplements ready for prime time? J Clin Psychiatry. 2008;69(9):1497-1498.
58. Pinzello A, Andreoli V. Le transmetilazioni SAM-dipendenti nelle sindromi depressive. Valutazione dell-effetto terapeutico della S-adenosilmetionina con la scala di Hamilton. Quad Ter Sper Suppl Bioch Biol Sper. 1972;X/2:3-11. Italian.
59. Fazio C, Andreoli V, Agnoli A, et al. Effetti terapeutici e meccanismo d'azione della S-adenosil-L-metionina (SAMe) nelle sindromi depressive [Therapeutic effects and mechanism of action of S-adenosyl-L-methionine (SAM) in depressive syndromes]. Minerva Med. 1973;64:1515-1529. [Article in Italian].
60. Agnoli A, Fazio C, Andreoli V, et al. Disturbi neuropsichiatrici e transmetilazioni. Effetti terapeutici della S adenosil-L-metionina [Neuropsychiatric disorders and transmethylation: therapeutic effects of S-adenosyl-L-methionine]. Clin Ter. 1975;75:567-579. [Article in Italian].
61. Mantero M, Patorino P, Carolei A, et al. Controlled double-blind study (SAMe-imipramine) in depressive syndromes. Minerva Med. 1975;66(78):4098-4101.
62. Andreoli V, Campedelli A, Maffei F. La S-adenosil-L-metionina (SAMe) in geropsichiatria: uno studio clinico controllato "in aperto" nelle sindromi depressive. Minerva Psichiatr. 1978;25:172-180. Italian.
63. Barberi A, Pusateri C. Sugli effetti clinici della S-adenosil-Lmetionina (SAMe) nelle sindromi depressive dell'eta' senile. Minerva Psichiatr. 1978;19:235-243. Italian.
64. Salvadorini F, Galeone F, Saba P, et al. Evaluation of s-adenosylmethionine (SAMe) effectiveness on depression. Curr Ther Res. 1980;27:908-918.
65. Carney MW, Martin R, Bottiglieri T, et al. Switch mechanism in affective illness and S-adenosylmethionine. Lancet. 1983;1(8328):820-821.
66. Hardy M, Coulter I, Morton SC, et al. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ): 2002 [cited 2011 Oct 29]. Available from: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1a. section.
67. Evidence Report/Technology Assessment no 64. AHRQ publication no 02-E034. Prepared by Southern California Evidence-based Practice Center under contract no 290-97-0001.
68. Miccoli L, Porro V, Bertolino A. Comparison between the antidepressant activity of S-adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli). 1978;33(3):243-255.
69. Scarzella R, Appiotta A. Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. Riv Sper Freniatr Med Leg Alien Ment. 1978;102:359-365. Italian.
70. Monaco P, Quattrocchi F. Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methionine or SAM) [Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methione or SAM)]. Riv Neurol. 1979;49(6):417-439. [Article in Italian].
71. Küfferle B, Grünberger J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. Adv Biochem Psychopharmacol. 1982;32:175-180.
72. Janicak PG, Linpinski J, Davis JM, et al. S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci. 1988;25(3):306-313.
73. Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr. 2002;76(5):1172S-1176S.
74. Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L- methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 2002;5(4):287-294.
75. Agnoli A, Andreoli V, Casacchi M. Effect of S-adenosyl-Lmethionine (SAMe) upon depressive symptoms. J Psychiatr Res. 1976;13(1):43-54.
76. Muscettola G, Galzenati M, Balbi A. SAMe versus placebo: a double blind comparison in major depressive disorders. Adv Biochem Psychopharmacol. 1982;32:151-156.
77. De Leo D. S-adenosylmethionine as an antidepressant. Curr Ther Res. 1987;41(6):865-870.
78. Carney MW, Edeh J, Bottiglieri T, et al. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neurophrmacol. 1986;9(4):379-385.
79. Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med. 1987;83(5A):66-71.
80. Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096-1098.
81. Castagna A, Le Grazie C, Accordini A. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurology. 1995;45(9):1678-1683.
82. De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. Curr Ther Res. 1992;52(3):478-485.
83. Bell KM, Potkin SG, Carreon D, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand. 1994;89(154):15-18.
84. Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom. 1993;59(1):34-40.
85. Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 1990;147(5):591-595.
86. Fava M, Rosenbaum JF, Birnbaum R, et al. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand. 1992;86(1):42-45.
87. Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-Lmethionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004;24(6):661-664.
88. Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992;44(3):257-262.
89. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942-948.
90. Carney MW, Chary TK, Bottiglieri T, et al. The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry. 1989;154:48-51.
91. Iruela LM, Minguez L, Merino J, et al. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry. 1993;150(3):522.